Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05207631
Other study ID # 010322
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date January 24, 2023

Study information

Verified date January 2023
Source Hôpital Fribourgeois
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The drug treatment of chronic obstructive pulmonary disease (COPD) is mainly based on inhaled therapy. This route of administration is limited by inhaler handling errors, insufficient inspiratory flow or inappropriate inhalers. According to the scientific literature, these limitations are extremely common in both outpatients and inpatients. Our hypothesis is that the implementation of a standardised and systematic assessment of inhalers combined with a prescribing guide to help select a suitable inhaler will decrease the proportion of suboptimally used inhalers at discharge in patients hospitalised with a diagnosis of COPD. To assess the effectiveness of our intervention, the investigators will compare the proportion of inhalers used suboptimally at hospital discharge between a control cohort before the implementation of our intervention and a cohort after the implementation of our intervention. Secondary outcomes include reasons for sub-optimal use of inhalers, i.e. inhaler handling errors, insufficient peak inspiratory flow or inappropriate inhaler. Secondary outcomes will also include length of hospital stay and 30-day readmission rate.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date January 24, 2023
Est. primary completion date December 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Admission to the HFR Fribourg internal medicine department 2. Age greater than or equal to 18 years 3. Diagnosis of COPD 4. Use of an inhaler device for the treatment of COPD before admission Exclusion Criteria: 1. Inability to complete initial assessment due to language problems 2. Inability to complete initial assessment due to physical or mental conditions 3. Patient who has already received the intervention during a previous hospitalization. 4. Length of hospitalization of less than 72 hours 5. Patient already included in the control period

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Systematic and standardised assessment of inhalers and implementation of a prescribing guide
Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.

Locations

Country Name City State
Switzerland HFR Fribourg Fribourg

Sponsors (1)

Lead Sponsor Collaborator
Hôpital Fribourgeois

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of inhalers used sub-optimally at hospital discharge An inhaler used sub-optimally is defined as an inhaler used with at least one critical error and/or with insufficient inspiratory flow. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of inhaler used with a critical error at hospital discharge In accordance with the literature, the investigators define critical error as an action or an inaction that in itself would have a detrimental impact of the delivery of the drug to the distal airways. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of inhaler used with suboptimal peak inspiratory flow at hospital discharge. The peak inspiratory flow values considered sub-optimal for inhaler use are defined in the literature and are specific to each inhaler type. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of inhalers that cannot be handled properly despite appropriate teaching at hospital discharge. If critical errors are identified in the handling of the inhaler, the physiotherapist provides targeted instruction to correct these errors. After each instruction, a new assessment of the inhaler technique is performed and the instruction is repeated if a critical error persists. If handling critical errors persist despite appropriate instruction, it's considered that the inhaler cannot be handled by the patient. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of inappropriate inhaler at hospital discharge. An inhaler is considered unsuitable if the patient is unable to handle it properly after appropriate instruction and/or if the patient does not have sufficient inspiratory flow for optimal use of the inhaler. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of inhalers used sub-optimally at hospital discharge by type of inhaler. The proportion of inhalers used sub-optimally at hospital discharge is described by type of inhaler. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Proportion of patients using at least one inhaler sub-optimally A participant is considered to have suboptimal device use if making a critical error when using an inhaler or if their peak inspiratory flow rate is insufficient for optimal device use. This outcome is assessed within 48 hours prior to hospital discharge
Secondary Length of hospital stay The length of stay in acute care on the internal medicine department will be documented. This outcome is assessed up to three months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A